Legend Biotech Corp (LEGN) SEC Filings — 2024
37 SEC filings for Legend Biotech Corp (LEGN) in 2024.
Filings
- Legend Biotech CFO Resigns Effective Jan 2, 2025 — 6-K · Dec 23, 2024
- Legend Biotech Files 6-K Reporting Status — 6-K · Dec 10, 2024
- Legend Biotech Corp SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- Legend Biotech Files 6-K with Q3 2024 Financial Updates — 6-K · Nov 12, 2024
- Legend Biotech Corp SC 13G/A Filing — SC 13G/A · Nov 12, 2024
- Legend Biotech Files Routine 6-K Report — 6-K · Nov 5, 2024
- Legend Biotech AGM Disrupted by Power Outage — 6-K · Oct 22, 2024
- Legend Biotech Holds 2024 Shareholder Meeting — 6-K · Oct 21, 2024
- Legend Biotech CARVYKTI® Sales Hit $286M — 6-K · Oct 15, 2024
- Legend Biotech Files 6-K, Confirms 20-F Reporting — 6-K · Sep 27, 2024
- Legend Biotech Sets Shareholder Meeting for Oct 21 — 6-K · Sep 20, 2024
- Legend Biotech's Cilta-cel Approved in China for Multiple Myeloma — 6-K · Aug 27, 2024
- Legend Biotech Files 6-K for Q2 2024 — 6-K · Aug 9, 2024
- Legend Biotech Files 6-K Report — 6-K · Aug 8, 2024
- Legend Biotech Files Routine 6-K Disclosure — 6-K · Jul 26, 2024
- Legend Biotech CARVYKTI Sales Hit $186M — 6-K · Jul 17, 2024
- Legend Biotech Files 6-K, Confirms 20-F Reporting — 6-K · Jul 2, 2024
- Legend Biotech Presents CARVYKTI Data at ASCO and EHA — 6-K · Jun 3, 2024
- Legend Biotech to Present CARVYKTI Data at ASCO and EHA — 6-K · May 23, 2024
- Legend Biotech Files 6-K for Q1 2024 — 6-K · May 13, 2024
- European Commission Approves Legend Biotech's CARVYKTI for 2nd-Line MM — 6-K · Apr 22, 2024
- Legend Biotech Files 6-K Report — 6-K · Apr 16, 2024
- FDA Approves Legend Biotech's CARVYKTI for Multiple Myeloma — 6-K · Apr 8, 2024
- Legend Biotech Corp SC 13G/A Filing — SC 13G/A · Apr 5, 2024
- Legend Biotech Signs Master Services Agreement with Novartis — 6-K · Mar 29, 2024
- Legend Biotech Corp Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 19, 2024
- Legend Biotech Files 6-K, Mentions FDA Advisory Committee — 6-K · Mar 15, 2024
- Legend Biotech Files 6-K on FDA Briefing Books — 6-K · Mar 13, 2024
- Legend Biotech Files 6-K for Q4 2023 Results — 6-K · Mar 11, 2024
- Legend Biotech Files 6-K as Foreign Private Issuer — 6-K · Feb 23, 2024
- Legend Biotech Corp SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Legend Biotech Corp SC 13G Filing — SC 13G · Feb 14, 2024
- Legend Biotech Corp SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- FMR LLC & Abigail Johnson Hold 7.04% Stake in Legend Biotech — SC 13G/A · Feb 9, 2024
- BlackRock Discloses 5.0% Stake in Legend Biotech Corp. — SC 13G · Jan 29, 2024
- Legend Biotech: CARVYKTI® Q4 Preliminary Sales Hit $159M — 6-K · Jan 23, 2024
- Legend Biotech Updates Corporate Presentation for J.P. Morgan Conference — 6-K · Jan 9, 2024